z-logo
Premium
B and T Cell Epitope‐Based Peptides Predicted from Evolutionarily Conserved and Whole Protein Sequences of Ebola Virus as Vaccine Targets
Author(s) -
Yasmin T.,
Nabi A. H. M. Nurun
Publication year - 2016
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/sji.12425
Subject(s) - epitope , biology , human leukocyte antigen , mhc class i , genetics , allele , virology , major histocompatibility complex , phylogenetic tree , mhc class ii , computational biology , antigen , gene
Ebola virus ( EBV ) has become a serious threat to public health. Different approaches were applied to predict continuous and discontinuous B cell epitopes as well as T cell epitopes from the sequence‐based and available three‐dimensional structural analyses of each protein of EBV . Peptides ‘ 79 VPSATKRWGFRSGVPP 94 ’ from GP 1 and ‘ 515 LHYWTTQDEGAAIGLA 530 ’ from GP 2 of Ebola were found to be the consensus peptidic sequences predicted as linear B cell epitope of which the latter contains a region 519 TTQDEG 524 that fulfilled all the criteria of accessibility, hydrophilicity, flexibility and beta turn region for becoming an ideal B cell epitope. Different nonamers as T cell epitopes were obtained that interacted with different numbers of MHC class I and class II alleles with a binding affinity of <100 n m . Interestingly, these alleles also bound to the MHC class I alleles mostly prevalent in African and South Asian regions. Of these, ‘ LANETTQAL ’ and ‘ FLYDRLAST ’ nonamers were predicted to be the most potent T cell epitopes and they, respectively, interacted with eight and twelve class I alleles that covered 63.79% and 54.16% of world population, respectively. These nonamers were found to be the core sequences of 15mer peptides that interacted with the most common class II allele, HLA ‐ DRB 1*01:01. They were further validated for their binding to specific class I alleles using docking technique. Thus, these predicted epitopes may be used as vaccine targets against EBV and can be validated in model hosts to verify their efficacy as vaccine.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here